Acute Lymphoblastic Leukemia in Children.

  title={Acute Lymphoblastic Leukemia in Children.},
  author={Stephen P. Hunger and Charles G. Mullighan},
  journal={The New England journal of medicine},
  volume={373 16},
The most common cancer in childhood is now curable in 90% of patients. Current efforts are focused on devising molecular-based therapy for the subsets of acute lymphoblastic leukemia that are most resistant to current therapy. 

Figures and Tables from this paper

Outcome of childhood acute lymphoblastic leukemia treatment in a single center in Brazil: A survival analysis study
There are few studies that demonstrate the results in Brazil and the probability of current overall survival (OS) is around 90% in developed countries.
Genomics in childhood acute myeloid leukemia comes of age
A Children's Oncology Group study of nearly 1,000 pediatric acute myeloid leukemia (AML) cases reveals marked differences between the genomic landscapes of pediatric and adult AML and offers
Outcomes of children and young adults with T‐cell acute lymphoblastic leukemia/lymphoma who present in critical status
Patients with T‐cell acute lymphoblastic leukemia and lymphoma (T‐ALL/LLy) commonly present with critical features such as hyperleukocytosis and mediastinal mass, which complicates completing a
Pediatric Acute Lymphoblastic Leukemia
Therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), are discussed in ONCOLOGY.
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors
B-cell acute lymphoblastic leukemia (B-ALL) can be cured in most children and in the majority of young adults with sufficiently intensive – and myelosuppressive – combination chemotherapy regimens ...
CAR-T Cells: An Innovative Therapeutic Strategy Against Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is a prevalent and highly progressive cancer in children and adolescents associated with an excessive production of immature lymphocytes in the bone marrow, which
Immunotherapy in Pediatric Acute Lymphoblastic Leukemia
Treatment for patients with B-ALL remains a therapeutic challenge despite successes due to multi-agent chemotherapy regiments, CNS prophylaxis and better risk stratification.
Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real‐world setting: Results from the NEUF study
Prior to regulatory approval of blinatumomab in pediatric patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell precursor acute lymphoblastic leukemia (R/R Ph− BCP‐ALL),
L‐asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study
The survival of children with acute lymphoblastic leukemia (ALL) has improved due to changes in the treatment and the disease diagnosis. A significant advance was the incorporation of asparaginase.
Thrombotic potential during pediatric acute lymphoblastic leukemia induction: Role of cell‐free DNA
Thromboembolism affects up to 30% of children undergoing treatment for acute lymphoblastic leukemia (ALL). Increased thrombin generation has been reported in ALL, but the mechanisms remain elusive.


Treatment of childhood acute lymphoblastic leukemia in central America: A lower‐middle income countries experience
Five Asociación de Hemato‐Oncología de Centroamérica (AHOPCA) countries have used an adapted BFM‐based protocol for childhood acute lymphoblastic leukemia (ALL).
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
While relapse is the main contributor to poorer survival in DS-ALL, infection-associated TRM was increased in all protocol elements, unrelated to treatment phase or regimen.
Molecular pathogenesis of T-cell leukaemia and lymphoma
This Review focuses on the molecular mechanisms responsible for disease induction and maintenance in T-ALL and compares the physiological progression of T-cell differentiation with T- cell transformation, highlighting the close relationship between these two processes.
Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia
Improved risk stratification and chemotherapy have eliminated the previous independent prognostic significance of gender, CNS leukemia and translocation, whereas the post-induction level of minimal residual disease (MRD) has emerged as a new risk grouping feature.
Adolescents and young adults with acute lymphoblastic leukemia.
  • W. Stock
  • Medicine, Psychology
    Hematology. American Society of Hematology. Education Program
  • 2010
This review will describe current controversies surrounding the treatment of adolescents and young adults with ALL--a group who finds themselves in the transition from "pediatric" to "adult" treatment approaches.
Trends in childhood cancer incidence in the U.S. (1992–2004)
Examination of population‐based incidence data provides insight regarding etiology among various demographic groups and may result in new hypotheses, including Asian/Pacific Islanders and Hispanics, for whom to the authors' knowledge trends have not been previously examined.
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.
The occurrence of what the author interpreted as an "acceleration phenomenon" in the leukemic process as seen in the marrow and viscera of children with acute leukemia treated by the injection of folic acid conjugates1 and pteroyltriglutamic acid (teropterin) — and an experience gained from studies on folic .
Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.
  • S. HungerXiaomin Lu W. Carroll
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
This study documents ongoing survival improvements for children and adolescents with acute lymphoblastic leukemia, emphasizing that efforts to further improve survival must be directed at both high-risk subsets and at those children predicted to have an excellent chance for cure.
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children ’ s Oncology Group Study AALL 0031
Longer-term follow-up confirms the initial observation of substantially good outcomes for children and adolescents with Ph + ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.
Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?
  • E. RaetzT. Bhatla
  • Medicine, Biology
    Hematology. American Society of Hematology. Education Program
  • 2012
High-resolution genomic analyses of matched pairs of diagnostic and relapse bone marrow samples are emerging as a promising tool for identifying pathways that impart chemoresistance in children with ALL.